Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average daily volume. This double-digit move lower was sparked by a $150 million public offering of its common stock.
Heron reportedly plans on using the proceeds from this secondary offering to support the ongoing commercial launches of its medicines for chemotherapy-induced nausea, Sustol and Cinvanti, as well as to fund its clinical activities.
Image source: Getty Images.
Source: Fool.com
Heron Therapeutics Inc. Stock
€2.58
-8.050%
With 10 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 4 € shows a very positive potential of 55.28% compared to the current price of 2.58 € for Heron Therapeutics Inc..
